A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

Summary

This study is a randomized, double-blind, double-dummy,placebo parallel controlled, multi-centre,phase III clinical trial to evaluate the efficacy and safety of TQB2450 with or without anlotinib compared with placebo as consolidation treatment in subjects with locally advanced/unresectable (Stage III) Non-Small Cell Lung Cancer that has not progressed after prior concurrent/sequential chemoradiotherapy.

Timeline

Start

2020-05-27

Primary completion

2022-12

Completion

2025-03

Publications

• Dong B, Chen L, Pang Q, Jiang O, Ge H, Cheng Y, Zhou R, Meng X, Li J, Zhu X, Wang X, Cao Q, Ji Y, Chen M. TQB2450 with or without anlotinib as maintenance treatment in subjects with locally advanced/unresectable non-small cell lung cancer that have not progressed after prior concurrent/sequential chemoradiotherapy (R-ALPS): study protocol for a randomized, double-blind, placebo-controlled, multicenter phase III trial. Transl Lung Cancer Res. 2024 Oct 31;13(10):2828-2837. doi: 10.21037/tlcr-24-362. Epub 2024 Oct 28.

Drugs

Indications